Wall Street Analysts Are Bullish on Top Healthcare Picks


There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Moleculin Biotech (MBRX) and Ra Medical Systems Inc (RMED) with bullish sentiments.

Moleculin Biotech (MBRX)

Maxim Group analyst Jason McCarthy initiated coverage with a Buy rating on Moleculin Biotech today and set a price target of $3. The company’s shares closed yesterday at $1.35, close to its 52-week low of $1.03.

McCarthy commented:

“We are initiating coverage of $3 price target. Moleculin is an oncology-focused company with three differentiated programs for addressing cancer via: 1) STAT3 inhibition (WP1066); 2) chemotherapy (liposomal Annamycin); and 3) glucose inhibition (WP1122).”

According to TipRanks.com, McCarthy is a 1-star analyst with an average return of -1.5% and a 30.2% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Moleculin Biotech with a $5.50 average price target.

See today’s analyst top recommended stocks >>

Ra Medical Systems Inc (RMED)

Maxim Group analyst Anthony Vendetti maintained a Buy rating on Ra Medical Systems Inc today and set a price target of $23. The company’s shares closed yesterday at $8.23, close to its 52-week low of $7.50.

Vendetti noted:

“Market close, RMED reported better-than-expected 3Q18 revenue, driven by higher Vascular sales. However, this was mostly offset by lower gross margin and higher SG&A expenses, which led to a wider-than-expected EPS loss. RMED signed 26 new DABRA usage agreements in the quarter, bringing the total to 34 agreements. On 10/1/18, the company announced the closing of its IPO that raised net proceeds of $67.3M.”

According to TipRanks.com, Vendetti is a 4-star analyst with an average return of 8.8% and a 52.9% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Ellex Medical Lasers Limited, Restoration Robotics Inc, and Xtant Medical Holdings.

Ra Medical Systems Inc has an analyst consensus of Strong Buy, with a price target consensus of $20.75, implying a 152.1% upside from current levels. In a report released today, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $21 price target.

.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts